Judges Scientific CFO and Deputy Chair Boost Shareholdings via Dividend Reinvestment Programme

Brad Ormsby’s Share Acquisition Through Dividend Reinvestment Programme

On 17 July 2026, Brad Ormsby, Chief Financial Officer of Judges Scientific plc, purchased 63 ordinary shares via the company’s automatic dividend reinvestment programme. The shares were acquired at 4917.5 pence each on the London Stock Exchange AIM Market under ticker JDG. This initial notification reflects joint shareholding accumulation by Ormsby and his spouse.

Utilizing the dividend reinvestment programme indicates a systematic approach to increasing equity holdings by converting dividend payments into additional shares rather than direct cash purchases. For the CFO, responsible for capital management and cash allocation, this move signals confidence in the sustainability of the group’s dividends and its future earnings potential. The transaction was disclosed in compliance with UK market abuse regulations governing director share dealings.

Ralph Elman’s Significant Stake Increase as Non-Executive Deputy Chair

Ralph Elman, Non-Executive Deputy Chair, acquired 122 ordinary shares through the dividend reinvestment programme on 17 July 2026, nearly doubling the volume purchased by Ormsby. The transaction occurred at the same price of 4917.5 pence per share on the AIM Market. Despite his non-executive role, Elman’s larger purchase highlights a strong commitment to building his equity position.

Elman’s governance role involves oversight rather than daily management, yet his participation in the dividend reinvestment programme underscores ongoing confidence in the company’s shareholder value creation. This initial notification ensures transparency regarding beneficial interests held by persons discharging managerial responsibilities or their associates. Such insider purchases are closely monitored by investors as potential indicators of management sentiment about company prospects.

Judges Scientific’s Focus on Scientific Instrument Sector and Acquisition Strategy

Judges Scientific plc operates as a consolidator in the scientific instrument sector, having acquired 25 companies since 2005. The group targets businesses that align with its operational and financial criteria, integrating them into its portfolio to drive inorganic growth.

Most acquired companies are UK-based, leveraging the country’s reputation as a centre of excellence in scientific instrument manufacturing and development. These businesses serve a global customer base including higher education, scientific research, industrial manufacturers, and regulatory bodies. The group has earned five Queen’s Awards for innovation and export, reflecting the quality and international competitiveness of its portfolio. The business model focuses on sustainable profit and cash generation, with shareholder returns driven by debt reduction, organic growth, and dividends.

Market Profile of Judges Scientific’s Portfolio Companies

The 25 portfolio businesses operate in global niche markets characterized by long-term growth and resilient profit margins. These specialized markets provide barriers to entry, differentiated products, and less price-sensitive customers, supporting sustainable profitability.

Technical specialization, regulatory requirements, and limited addressable markets contribute to margin resilience, enabling dividend payments even during economic cycles. The global reach of these products exposes the group to international scientific funding and manufacturing trends, which may not directly correlate with UK economic conditions.

Dividend Reinvestment Programme as a Capital Management Strategy

The dividend reinvestment programme used by both directors is a common shareholder capital management tool allowing automatic reinvestment of dividends into shares without separate cash transactions. This programme reflects Judges Scientific’s confidence in maintaining regular dividends and offers a tax-efficient way for shareholders to compound holdings.

Senior management participation, especially by the CFO and Non-Executive Deputy Chair, signals conviction in the company’s dividend sustainability and future earnings. The CFO’s involvement is particularly significant given his insight into cash flow and capital allocation. By reinvesting dividends, Ormsby and Elman express confidence that this capital will yield returns exceeding the dividend yield and support ongoing shareholder value creation.

Transaction Details and AIM Market Execution

Both share purchases were executed on 17 July 2026 on the London Stock Exchange AIM Market at 4917.5 pence per ordinary share. The AIM Market offers a regulated environment for smaller and mid-cap companies, balancing investor protections with flexible listing requirements. Judges Scientific’s AIM listing aligns with its market capitalization and liquidity profile while ensuring compliance with disclosure and market abuse regulations.

The identical share price for both transactions suggests execution during a stable pricing period or a single calculated daily price for the dividend reinvestment programme. The ordinary shares carry ISIN GB0032398678 and represent voting equity interests. The XLON designation confirms the trading venue and regulatory transparency.

Regulatory Disclosure and Compliance with Market Abuse Rules

This announcement fulfills UK market abuse regulation and AIM Rules for Companies disclosure requirements concerning persons discharging managerial responsibilities (PDMRs). Both Brad Ormsby and Ralph Elman are classified as PDMRs. These transactions are reported as "initial notifications," indicating the first formal disclosure of their shareholding activity under the dividend reinvestment programme.

The disclosure includes director names and statuses, issuer legal entity identifier (LEI: 2138004EXWWPTW1JOL31), instrument details, transaction nature and price, volume, date, and execution venue. This comprehensive reporting ensures investors receive timely, standardized information on insider holdings, promoting market fairness and transparency.

Insider Confidence Reflected in Director Share Accumulation

The additional share purchases by the CFO and Non-Executive Deputy Chair via dividend reinvestment may indicate insider confidence in Judges Scientific’s operational outlook and shareholder value trajectory. Insider accumulation, especially through automatic reinvestment, can signal beliefs that shares are undervalued or that future earnings growth supports continued investment. However, such interpretations should be considered alongside broader market and company fundamentals.

Patterns of director share purchases provide insight into management alignment with shareholders and consistency of insider investment behavior. The simultaneous transactions by directors in different governance roles at identical pricing suggest scheduled dividend reinvestment rather than discretionary buys. Investors may monitor future dividend reinvestment dates for similar insider activity.

Strategic Outlook of Judges Scientific’s Consolidation Approach

Judges Scientific’s acquisition-driven consolidation strategy addresses the fragmented nature of the scientific instrument sector, where many companies remain independent or family-owned. The group’s successful acquisition of 25 businesses since 2005 demonstrates effective deal sourcing and integration capabilities. The sustainability of this pipeline will impact long-term earnings growth and shareholder returns.

The portfolio’s niche market positioning offers resilience against disruption, supported by technical specialization and regulatory barriers. However, evolving market dynamics such as larger industrial entrants or digital transformation could influence future consolidation. The directors’ dividend reinvestment purchases may reflect confidence in the current portfolio and acquisition strategy’s ability to generate sustainable returns, despite inherent operational risks.